Commonwealth Equity Services LLC Has $180,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

Commonwealth Equity Services LLC grew its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 17.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,952 shares of the company’s stock after buying an additional 4,785 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Verve Therapeutics were worth $180,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. State Street Corp lifted its stake in shares of Verve Therapeutics by 27.0% in the third quarter. State Street Corp now owns 4,253,217 shares of the company’s stock worth $20,586,000 after buying an additional 903,809 shares during the last quarter. Geode Capital Management LLC raised its holdings in Verve Therapeutics by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company’s stock worth $7,749,000 after acquiring an additional 40,915 shares during the period. FMR LLC lifted its position in Verve Therapeutics by 0.3% during the 3rd quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after acquiring an additional 3,873 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Verve Therapeutics by 28.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 572,173 shares of the company’s stock valued at $2,769,000 after acquiring an additional 126,110 shares during the period. Finally, Barclays PLC grew its position in shares of Verve Therapeutics by 139.8% in the third quarter. Barclays PLC now owns 222,919 shares of the company’s stock valued at $1,079,000 after purchasing an additional 129,944 shares during the last quarter. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Trading Down 10.6 %

Verve Therapeutics stock opened at $3.05 on Friday. The company has a market cap of $270.83 million, a PE ratio of -1.24 and a beta of 1.86. The company’s 50-day moving average is $6.09 and its two-hundred day moving average is $5.94. Verve Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $9.31.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.14. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Research analysts forecast that Verve Therapeutics, Inc. will post -2.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on VERV shares. Guggenheim reiterated a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. Royal Bank of Canada reduced their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $20.67.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.